In recent years, human studies have made enormous contributions towards an understanding of the genetic basis of diabetes mellitus; however, most of the experimentation needed for the invention and testing of novel therapeutic approaches cannot be performed in humans. Thus, there is no alternative to appropriate animal models. In Animal Models in Diabetes Research, expert researchers explore the current status of the most important models and procedures in order to provide a timely resource in experimental diabetology. The first half of the volume serves as a comprehensive overview on our current knowledge of the pathogenesis and pathophysiology of diabetes in animal models through a series of reviews in model strains. The book then continues with vital, established protocols that are employed in the characterization and study of animal models of diabetes. As a volume in the highly successful Methods in Molecular BiologyTM series, this work contains the type of detailed description and key implementation advice necessary to achieve successful results. Authoritative and cutting-edge, Animal Models in Diabetes Research delivers essential content that will be an important resource to advance diabetes research in the years to come.

This book aims to aid the selection of the most appropriate methods for use in early phase (1 and 2) clinical studies of new drugs for diabetes, obesity, non-alcoholic fatty liver disease (NAFLD) and related cardiometabolic disorders. Clinical research methods to assess the pharmacokinetics and pharmacodynamics of new diabetes drugs, e.g. the euglycemic clamp technique, have become well-established in proof-of-mechanism studies. However, selection of the most appropriate techniques is by no means straightforward. Moreover, the application of such methods must conform to the regulatory requirements for new drugs. This book discusses the need for new pharmacotherapies for diabetes, obesity and NAFLD and the molecular targets of drugs currently in development. Emerging technologies including functional imaging, circulating biomarkers and omics are considered together with practical and ethical issues pertaining to early phase clinical trials in subjects with cardiometabolic disorders. Translational Research Methods in Diabetes, Obesity, and Non-Alcoholic Fatty Liver Disease is of interest to biomedical scientists, pharmacologists, academics involved in metabolic research and clinicians practicing in these specialties.

An extremely useful text for research Internationally renowned experts describe the models, provide data obtained with those models, and discuss the relative usefulness of models in relation to the diabetic syndrome in humans. The first section examines the most widely used model, the streptozotocin (STZ) rat, condensing a massive quantity of literature to present both the general effects of of STZ diabetes and the effects on individual organ systems. The second section discusses less well-known and more recent diabetic models, such as the BB rat, the NOD mouse and Zucker and Zucker Diabetic Fatty rat models. Genetic models of insulin dependent diabetes mellitus (IDDM) are examined and compared to chemically induced IDDM models.

This important reference, edited by Ronald Ross Watson and Betsy Dokken, collects the research needed to make the distinct connection between pre-diabetes, diabetes, and cardiovascular disease. Glucose Intake and Utilization in Pre-Diabetes and Diabetes: Implications for Cardiovascular Disease explains the mechanisms of progression from pre-diabetes to diabetes to cardiovascular disease. Since pre-diabetes and diabetes are important cardiovascular disease risk factors, and impaired glucose metabolism among cardiac patients is extremely prevalent, the importance of reviewing pre-diabetes and its involvement in CVD complications is vital as one applies food and glycemic control to slow progress to diabetes and heart disease. The book further focuses on glucose intake and utilization in diabetes, including coverage of diabetes in the development and pathology of cardiovascular disease, risks and epidemiology of cardiovascular problems promoted by diabetes, macrovascular effects and their safety in therapy of diabetics, beta cell biology and therapy of diabetes, and nutrition to modulate diabetes.

The world has recorded losses in terms of human life as well as extensive time spent in experimentation with development of new drugs, elucidation of disease mechanism(s), and therapeutic agent discovery. Ethical and legal issues cojoin in slowing down scientific discoveries in medicine and biology. The past two (2) decades, therefore, have seen tremendous attempts that largely are successful in developing animal models with the characteristics of mimicking, approximating, or expressing transplanted human organs/tissues. These models or rather approaches seem to be fast, cost-effective, and easy to maintain compared to primates. This book is a collection of expert essays on animal models of human diseases of global interest. A visible objective of the book is to provide real-time experimental approach to scientists, clinicians, ethicists, medicolegal/medical jurisprudence workers, immunologists, postgraduate students, and vaccinologists and informative and multidisciplinary approach for the identification of new therapeutic targets and biomarkers using animal models as well as investigating the pathogenesis and therapeutic strategies of human diseases. An increased understanding of the genetic, molecular, and cellular mechanisms responsible for the development of human diseases has laid out the foundation for the development of rational therapies mainly with animal models.

The term prediabtes has been defined as the condition of those persons who are predisposed to hyperglycemia, but in whom no abnormalities of carbohydrate metabolism is demonstrable. The contributors to these proceedings address the issues involved in determining how early in life the disease trend i

The 4th edition of this successful reference book contains an updated selection of the most frequently used assays for reliably detecting the pharmacological effects of potential drugs. Effects covered include cardiovascular, analgesic, endocrine, psychotropic, respiratory, renal and immunomodulatory activities. Each of the more than 1,000 assays comprises a detailed protocol outlining the purpose and rationale of the method, a critical assessment of the results and their pharmacological and clinical relevance. In addition, animal models of rare diseases are described. For this 4th edition, all existing chapters have been revised and completely updated. A large number of assays were added. Sections that have been specifically enlarged include - Pharmacological assays in thrombosis and haemostasis, - Antidiabetic activity (includes completely new chapters such as Biochemical Methods in Diabetology), - Anti-atherosclerotic activity. New chapters are added such as Auditory Pharmacology, Oncology Activity, Stem Cells, Omics, Personalized Medicine, etc.